Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation

被引：0
|
作者：
LN Türkeri
O Ayaz
M Özyürek
A Akdas
机构：
[1] ‘Ergun Özalp’ Research Laboratory,Department of Urology
[2] Marmara University School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 1999年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：S33 / S33
相关论文
共 50 条
  • [31] Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
    Smith, DC
    Chay, CH
    Dunn, RL
    Fardig, J
    Esper, P
    Olson, K
    Pienta, KJ
    CANCER, 2003, 98 (02) : 269 - 276
  • [32] ORAL ETOPOSIDE IN THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER
    HUSSAIN, MH
    PIENTA, KJ
    REDMAN, BG
    CUMMINGS, GD
    FLAHERTY, LE
    CANCER, 1994, 74 (01) : 100 - 103
  • [33] Induction of apoptosis in human hormone-refractory prostate cancer cell lines by using resveratrol in combination with AT-101
    Aktepe, Necmettin
    Yukselten, Yunus
    ANDROLOGIA, 2022, 54 (01)
  • [34] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Soga, Norihito
    Kato, Manabu
    Nishikawa, Kouhei
    Hasegawa, Yoshihiro
    Yamada, Yasushi
    Kise, Hideaki
    Arima, Kiminobu
    Sugimura, Yoshiki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 130 - 135
  • [35] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
  • [36] Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
    Morita, Tatsuo
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2010, 3 : 39 - 41
  • [37] Combination therapy in hormone-refractory prostate cancer
    Daniel P. Petrylak
    Current Oncology Reports, 2001, 3 (5) : 453 - 453
  • [38] Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer
    Ide, Hiroki
    Kikuchi, Eiji
    Kono, Hidaka
    Nagata, Hirohiko
    Miyajima, Akira
    Nakagawa, Ken
    Ohigashi, Takashi
    Nakashima, Jun
    Oya, Mototsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 79 - 84
  • [39] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Norihito Soga
    Manabu Kato
    Kouhei Nishikawa
    Yoshihiro Hasegawa
    Yasushi Yamada
    Hideaki Kise
    Kiminobu Arima
    Yoshiki Sugimura
    International Journal of Clinical Oncology, 2009, 14 : 130 - 135
  • [40] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
12345